AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating ...

AbbVie ABBV stock has gained 16.1% so far this year compared with an increase of 4.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.

Getty Images. Hmm...that might be a tall order for you. It would be for most Americans. Even if you could swing it by putting most of your portfolio into AbbVie, you'd then have too many eggs in ...

AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s ...

(Reuters) -AbbVie on Thursday cut its 2025 adjusted profit forecast as the drugmaker expects to incur $248 million in acquisition expenses related to milestone payments as well as research and ...

Deep-pocketed investors have adopted a bullish approach towards AbbVie ABBV, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

So, you want to invest in AbbVie (ABBV-0.42%) because it's a promising dividend-paying stock, and you also want to receive $1,000 per year in dividend income from it. How many shares should you buy?